NIH Locks Doors for Secret Grant Review Sessions in August
Published Date: 7/17/2025
Notice
Summary
The Center for Scientific Review is holding several closed virtual meetings in August 2025 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for health research. Scientists and organizations applying for grants should watch these dates closely as they impact funding decisions.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
Closed NIH grant review meetings
If you applied for the NIH grants listed, NIH will hold closed virtual meetings on August 12, 13, 14, and 18, 2025 to review and evaluate grant applications and decide funding. These meetings are scheduled as virtual sessions at the NIH Rockledge address and are specifically for evaluating grant applications.
SBIR Phase IIB review for small businesses
If you are a small business applying for the NHLBI SBIR Phase IIB Small Market and Bridge Awards, a closed virtual review will take place on August 13, 2025 from 9:00 a.m. to 5:00 p.m. to review and evaluate those grant applications.
Confidentiality of grant application information
The meetings are closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) so grant applications and discussions that could disclose confidential trade secrets, patentable material, or personal information will be protected from public disclosure. If you submit an application, information tied to your application is being handled under those privacy and trade-secret protections.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-13365, Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Unmanned Aircraft Systems (UAS) and Their Parts and Components
The government is checking if importing drones and their parts could affect our national security. If you make, sell, or use drones, now’s your chance to share your thoughts before any new rules are made. Comments are open soon, so don’t miss out on helping shape the future of drone imports and trade!
Next: 2025-13356, Constellation Energy Generation, LLC; Dresden Nuclear Power Station, Units 2 and 3; Quad Cities Nuclear Power Station, Units 1 and 2; Exemption
Constellation Energy got the green light to use a new safety inspection rule a bit later than planned at Dresden and Quad Cities nuclear plants. This change affects how and when they check important equipment but won’t cost extra or cause delays. It helps keep the plants safe while giving them some scheduling wiggle room.